Please assess the completion status of the following clinical trial:

Trial Title: Insulin Glargine All to Target Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
* Male or female patients~* 30 to 80 years of age~* Body Mass Index \<45 kg/m2~* With Type 2 diabetes mellitus for at least 2 years~* With an HbA1c level at screening of \>7.5% and \>7.0% at randomization~* On stable dual or triple oral therapy for at least 3 months~* Oral agents in 2 or 3 of the following classes: SU or repaglinide, biguanide, or TZD, willing and able to perform self-monitoring of BG~* Females of child-bearing potentially were required to be willing and able to use adequate contraception

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Lantus/Apidra-3 (Type: EXPERIMENTAL): Insulin glargine (Lantus) plus up to 3 injections of insulin glulisine (Apidra) added to oral agents.
- Lantus/Apidra-1 (Type: EXPERIMENTAL): Insulin glargine (Lantus) plus up to 1 injection of insulin glulisine (Apidra) added to oral agents.
- Novolog Mix 70/30 (Type: EXPERIMENTAL): Premixed insulin (Novolog® Mix 70/30) added to oral agents.

Based on this trial design, predict the completion outcome and termination type (if applicable).